☆ 4.7 Article

Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

Related references

Note: Only part of the references are listed.

Review Oncology

Immune-checkpoint inhibitors: long-term implications of toxicity

Douglas B. Johnson et al.

Summary: Immune-checkpoint inhibitors have improved outcomes for advanced-stage solid tumour patients, but they also carry the risk of chronic toxicities that can affect patients' quality of life. While evidence on chronic toxicities is limited, emerging evidence suggests that they may be more common than previously thought. These toxicities can affect various organ systems and may even lead to fatal outcomes. Research on the effects of immune-checkpoint blockade on other immune processes is also important for cancer survivors.

NATURE REVIEWS CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma

Kennedy Yao Yi Ng et al.

Summary: A study on advanced hepatocellular carcinoma patients treated with immune checkpoint inhibitors shows an association between immune-related adverse events and efficacy, with more severe events linked to better prognosis. Prompt use of systemic corticosteroids in patients experiencing adverse events is crucial for ensuring optimal long-term outcomes.

LIVER CANCER (2022)

Add to Collection

Article Oncology

Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis

Nuttapong Ngamphaiboon et al.

Summary: In Thai cancer patients treated with immune-checkpoint inhibitors (ICIs), immune-related adverse events (irAEs) were commonly observed, mainly low-grade and manageable. Re-occurrence of irAEs after re-challenging with ICIs was not uncommon. Patients with irAEs may have significantly longer overall survival (OS) compared to those without irAEs.

BMC CANCER (2021)

Add to Collection

Correction Oncology

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate O17 and O57: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer (vol 39, pg 723, 2021)

Borghaei

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Interferon-Gamma-Producing CD8+ Tissue Resident Memory T Cells Are a Targetable Hallmark of Immune Checkpoint Inhibitor-Colitis

Sarah C. Sasson et al.

Summary: Our study demonstrates that CD8(+) tissue resident memory T (T-RM) cells are the main activated T cell subset in ICI colitis. The pattern of gastrointestinal immunopathology in ICI colitis is distinct from ulcerative colitis at both the immune and epithelial-signaling levels. Activation of CD8+ T-RM cells correlates with clinical and endoscopic severity of ICI colitis.

GASTROENTEROLOGY (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Viral myocarditis: 1917?2020: From the Influenza A to the COVID-19 pandemics * , ** , ?

Shereif H. Rezkalla et al.

Summary: Myocarditis is common in viral infections, with elevated troponin in 36% of COVID patients. Diagnostic tools include ECG, echocardiogram, and cardiac MRI. Cardiac inflammation can result from viral invasion or cytokine storm.

TRENDS IN CARDIOVASCULAR MEDICINE (2021)

Add to Collection

Article Oncology

Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes

Aanika Balaji et al.

Summary: Steroid-refractory ICI-pneumonitis accounted for 18.5% of multidisciplinary irAE care referrals. This condition often occurred early in patients' treatment courses and most commonly presented with a diffuse alveolar damage (DAD) radiographic pattern. Patients treated with IVIG alone showed improvement in level-of-care and oxygenation requirements, with lower fatality rates (43%) compared to those treated with infliximab (100% mortality).

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection

Article Oncology

Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events

Jia Luo et al.

Summary: The study evaluated the management and outcomes of immune-related adverse events in lung cancer patients treated with immune checkpoint blockade. Results showed that while steroid-refractory or resistant irAEs events are rare, many patients with other irAEs remain refractory or experience toxicities from immunosuppression. Further understanding of the pathophysiology of specific irAEs is needed to guide treatments for severe irAEs effectively.

JOURNAL OF THORACIC ONCOLOGY (2021)

Add to Collection

Article Oncology

Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma

Caroline Robert et al.

Summary: The long-term safety and efficacy of pembrolizumab in treating melanoma were analyzed in a large population, showing no new toxicity signals after a lengthy follow-up period. The efficacy of pembrolizumab was similar regardless of the presence of immune-mediated adverse events or the use of systemic corticosteroids.

EUROPEAN JOURNAL OF CANCER (2021)

Add to Collection

Article Oncology

Delayed immune-related adverse events with an PD-1-based immunotherapy in melanoma

C. N. Owen et al.

Summary: This study revealed that delayed irAEs occur in approximately 5.3% of patients receiving anti-PD-1-based therapy, with common manifestations including colitis, rash, and pneumonitis. Some patients may experience severe symptoms and even death as a result of delayed irAEs.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Letter Oncology

Multiple immune-related toxicities in cancer patients treated with anti-programmed cell death protein 1 immunotherapies: a new surrogate marker for clinical trials?

A. Laparra et al.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Oncology

Original Research Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy

E. Ghisoni et al.

Summary: Late-onset and long-lasting immune-related adverse events (irAEs) during treatment with ICIs are common but underreported events that require time-dependent survival analysis to evaluate their impact on overall survival.

EUROPEAN JOURNAL OF CANCER (2021)

Add to Collection

Letter Oncology

Long-term impact of immunotherapy on quality of life of surviving patients: A multi-dimensional descriptive clinical study

Paul-Albert Domnariu et al.

EUROPEAN JOURNAL OF CANCER (2021)

Add to Collection

Review Endocrinology & Metabolism

Unravelling Checkpoint Inhibitor Associated Autoimmune Diabetes: From Bench to Bedside

Linda Wu et al.

Summary: Immune checkpoint inhibitors have greatly impacted oncological therapy, but have also led to a new set of immune related adverse events, including checkpoint inhibitor-related autoimmune diabetes. Studying autoimmune diabetes may help in identifying new therapeutic strategies.

FRONTIERS IN ENDOCRINOLOGY (2021)

Add to Collection

Article Oncology

Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy

Briana Rose Halle et al.

Summary: A retrospective cohort study on patients with pre-existing psoriasis receiving ICIs for cancer treatment showed that most patients experienced psoriasis exacerbation after treatment, but it was manageable with standard therapies; some patients also experienced other immune-related adverse events; patients with disease exacerbation performed well in terms of progression-free survival compared to those who did not.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection

Article Oncology

The Prognostic Significance of the Continuous Administration of Anti-PD-1 Antibody via Continuation or Rechallenge After the Occurrence of Immune-Related Adverse Events

Toshiya Fujisaki et al.

Summary: This study demonstrates that both the continuation and readministration of ICIs after irAE occurrence improved overall survival in NSCLC patients compared to permanent interruption.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Oncology

Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience

Vineel Bhatlapenumarthi et al.

Summary: This study investigated the frequency and severity of new immune-related adverse events (irAEs) in cancer patients treated with immune checkpoint inhibitors (ICIs), as well as the tolerability of ICIs upon rechallenge in patients with irAEs. Results showed that 25% of patients developed new irAEs, with 10% having preexisting autoimmune disorders (AIDs) and 7.3% requiring hospital admission due to irAEs. Majority of patients were treated for lung cancer and overall, ICIs were generally well tolerated with 6% of patients undergoing rechallenge successfully.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%

Martin Reck et al.

Summary: This study reports the first 5-year follow-up of a first-line immunotherapy trial for NSCLC, demonstrating that pembrolizumab provides a durable, clinically meaningful long-term overall survival benefit in first-line treatment of metastatic NSCLC with a PD-L1 tumor proportion score of at least 50%.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

Ronan J. Kelly et al.

Summary: In patients with resected esophageal or gastroesophageal junction cancer who had received neoadjuvant chemoradiotherapy, adjuvant therapy with nivolumab significantly improved disease-free survival compared to placebo.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Oncology

The Pattern of Time to Onset and Resolution of Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors in Cancer: A Pooled Analysis of 23 Clinical Trials and 8,436 Patients

Si-Di Tang et al.

Summary: This study revealed the general and specific occurrence pattern of immune-related adverse events induced by immune checkpoint inhibitors in various cancers, aiding in the comprehensive understanding, timely detection, and effective management of these adverse events.

CANCER RESEARCH AND TREATMENT (2021)

Add to Collection

Article Oncology

Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma

J. Randall Patrinely et al.

Summary: This multicenter cohort study found that chronic immune-related adverse events (irAEs) associated with anti-PD-1 therapy were more common than previously recognized, with a considerable proportion of patients developing chronic irAEs such as endocrinopathies and arthritis. Visceral organ-related irAEs had lower rates of becoming chronic, highlighting the importance of considering the risks of chronic irAEs in treatment decision-making.

JAMA ONCOLOGY (2021)

Add to Collection

Article Oncology

Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non-Small Cell Lung Cancer

Jia Luo et al.

Summary: Genetic differences in immunity may contribute to toxicity and outcomes with immune checkpoint inhibitor therapy. Thyroid immune-related adverse events were associated with response to anti-PD-1 therapy, and genetic risk for hypothyroidism was associated with the risk of developing thyroid irAEs.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy

Nicolas L. Palaskas et al.

Summary: A grading system was developed for ICI myocarditis based on degree of inflammatory infiltrate, with some patients able to continue ICI without immunosuppressive therapy and have good cardiovascular outcomes. Further studies are needed to identify low-risk patients who can safely receive ICI therapy.

EUROPEAN JOURNAL OF HEART FAILURE (2021)

Add to Collection

Article Medicine, General & Internal

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial

Enriqueta Felip et al.

Summary: IMpower010 study demonstrated a disease-free survival benefit with adjuvant atezolizumab versus best supportive care in patients who underwent complete resection followed by adjuvant chemotherapy, especially in the subgroup whose tumors expressed PD-L1 on 1% or more of tumor cells.

LANCET (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade

Miles C. Andrews et al.

Summary: The study showed that tumor-associated immune and genomic biomarkers of response to combined immune checkpoint blockade (CICB) in melanoma patients were similar to those of monotherapy, while toxicity from CICB was associated with a more diverse peripheral T-cell repertoire. Additionally, analysis of gut microbiota revealed a higher abundance of Bacteroides intestinalis in patients experiencing toxicity, along with an upregulation of the inflammatory factor IL-1 beta in colitis samples.

NATURE MEDICINE (2021)

Add to Collection

Review Oncology

The Inconsistent and Inadequate Reporting Of Immune-Related Adverse Events in PD-1/PD-L1 Inhibitors: A Systematic Review of Randomized Controlled Clinical Trials

Tong Xie et al.

Summary: This study evaluated the reporting of irAEs in RCTs of PD-1/PD-L1 inhibitors, finding inadequate reporting, inconsistencies in terminology and definitions, with higher quality associated with RCTs using combined immunotherapy.

ONCOLOGIST (2021)

Add to Collection

Article Oncology

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events

Julie R. Brahmer et al.

Summary: ICIs are standard treatments for cancer, but come with risks of immune-related adverse events. The SITC convened an expert panel to develop guidelines for managing irAEs, aiming to improve patient outcomes through evidence-based recommendations.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection

Correction Oncology

Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors (vol 9, e002890, 2021)

A. C. Guidon et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection

Article Urology & Nephrology

Acute Tubulointerstitial Nephritis in a Patient on Anti-Programmed Death-Ligand 1 Triggered by COVID-19: A Case Report

Dimitry Buyansky et al.

Summary: This case report describes a patient with stage 4 squamous cell carcinoma treated with a PD-L1 inhibitor who developed acute tubulointerstitial nephritis after contracting SARS-CoV-2, with rapid normalization of kidney function following high-dose corticosteroid therapy. The viral infection coupled with checkpoint inhibitor use may have created a proinflammatory environment leading to loss of self-tolerance to renal parenchyma, suggesting a potentially more significant role of viruses in autoimmunity in this patient population.

CANADIAN JOURNAL OF KIDNEY HEALTH AND DISEASE (2021)

Add to Collection

Article Oncology

Efficacy and safety of Infliximab for steroid-resistant immune-related adverse events: A retrospective study

Yukio Kadokawa et al.

Summary: This study investigated the outcomes of IFX treatment among 8 Japanese patients with various types of cancer, showing that some patients responded to IFX. However, potential CMV and CD infections should be recognized as concerns for patients receiving IFX treatment.

MOLECULAR AND CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer

Hossein Borghaei et al.

Summary: Immunotherapy with nivolumab has shown improved overall survival and safety compared to docetaxel in patients with advanced NSCLC in two phase III trials. Pooled 5-year data demonstrated a significant survival benefit with nivolumab and no new safety concerns.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

A multicenter characterization of hepatitis associated with immune checkpoint inhibitors

J. Randall Patrinely et al.

Summary: Immune-related hepatitis associated with immune checkpoint inhibitors has a median onset time of around two months, with most patients being asymptomatic or experiencing flu-like symptoms. Treatment usually involves glucocorticoids and second-line immunosuppression, with a modest risk of hepatitis recurrence when rechallenging with ICI therapy.

ONCOIMMUNOLOGY (2021)

Add to Collection

Article Oncology

Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management

Jaydira Del Rivero et al.

ONCOLOGIST (2020)

Add to Collection

Article Medicine, General & Internal

Glucocorticoid use and complications following immune checkpoint inhibitor use in melanoma

Kapil Agarwal et al.

CLINICAL MEDICINE (2020)

Add to Collection

Article Oncology

Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer

Charles Dolladille et al.

JAMA ONCOLOGY (2020)

Add to Collection

Article Oncology

Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis

Meghan J. Mooradian et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy

Adrienne M. Luoma et al.

CELL (2020)

Add to Collection

Article Oncology

Multiple Immune-Related Adverse Events and Anti-Tumor Efficacy: Real-World Data on Various Solid Tumors

Keitaro Shimozaki et al.

CANCER MANAGEMENT AND RESEARCH (2020)

Add to Collection

Article Oncology

Immune-related (IR)-pneumonitis during the COVID-19 pandemic: multidisciplinary recommendations for diagnosis and management

Jarushka Naidoo et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

Add to Collection

Review Medicine, General & Internal

Efficacy and Toxicity of Immune -Checkpoint Inhibitors in Patients With Preexisting Autoimmune Disorders

Michelle Coureau et al.

FRONTIERS IN MEDICINE (2020)

Add to Collection

Review Immunology

Immune checkpoint inhibitors therapies in patients with cancer and preexisting autoimmune diseases: A meta-analysis of observational studies

Wenhui Xie et al.

AUTOIMMUNITY REVIEWS (2020)

Add to Collection

Review Dermatology

Alopecia areata as an immune-related adverse event of immune checkpoint inhibitors: A review

Layal Antoury et al.

DERMATOLOGIC THERAPY (2020)

Add to Collection

Article Multidisciplinary Sciences

Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study

Naoto Okada et al.

SCIENTIFIC REPORTS (2020)

Add to Collection

Article Oncology

Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma

Caroline Robert et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Oncology

Multiorgan Immune-Related Adverse Events During Treatment With Atezolizumab

Ganessan Kichenadasse et al.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)

Add to Collection

Article Oncology

Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial

Paolo A. Ascierto et al.

LANCET ONCOLOGY (2020)

Add to Collection

Article Oncology

Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer

Bairavi Shankar et al.

JAMA ONCOLOGY (2020)

Add to Collection

Article Oncology

Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer

Marion Allouchery et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

Add to Collection

Article Medicine, General & Internal

Mycophenolate mofetil as a successful treatment of corticosteroid-resistant immune checkpoint inhibitor-induced hepatitis

Kenji Nakano et al.

OXFORD MEDICAL CASE REPORTS (2020)

Add to Collection

Article Oncology

Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade

Chipman R. G. Stroud et al.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2019)

Add to Collection

Article Oncology

Corticosteroids for the management of immune-related adverse events in patients receiving checkpoint inhibitors

Kiersten J. Williams et al.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2019)

Add to Collection

Review Endocrinology & Metabolism

Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints

Lee-Shing Chang et al.

ENDOCRINE REVIEWS (2019)

Add to Collection

Article Oncology

Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study

Alessio Cortellini et al.

ONCOLOGIST (2019)

Add to Collection

Review Oncology

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance

Filipe Martins et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2019)

Add to Collection

Article Oncology

Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy

Blake M. Warner et al.

ONCOLOGIST (2019)

Add to Collection

Article Oncology

The Impact of High-Dose Glucocorticoids on the Outcome of Immune-Checkpoint Inhibitor-Related Thyroid Disorders

Chanjuan Ma et al.

CANCER IMMUNOLOGY RESEARCH (2019)

Add to Collection

Article Oncology

Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer

Fiamma Berner et al.

JAMA ONCOLOGY (2019)

Add to Collection

Article Oncology

Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis

Hamzah Abu-Sbeih et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

Add to Collection

Article Oncology

Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study

Douglas B. Johnson et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

Add to Collection

Article Oncology

Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis

Hamzah Abu-Sbeih et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Article Biochemistry & Molecular Biology

A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis

Douglas B. Johnson et al.

NATURE MEDICINE (2019)

Add to Collection

Article Oncology

Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer

Audrey Simonaggio et al.

JAMA ONCOLOGY (2019)

Add to Collection

Article Oncology

Delayed immune-related events (DIRE) after discontinuation of immunotherapy: updates diagnostic hazard of autoimmunity at a distance

Marcus A. Couey et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

Add to Collection

Article Medicine, General & Internal

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

J. Larkin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Review Virology

Viruses and Autoimmunity: A Review on the Potential Interaction and Molecular Mechanisms

Maria K. Smatti et al.

VIRUSES-BASEL (2019)

Add to Collection

Article Rheumatology

Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study

Alice Tison et al.

ARTHRITIS & RHEUMATOLOGY (2019)

Add to Collection

Article Oncology

Unchecked immunity: a unique case of sequential immune-related adverse events with Pembrolizumab

N. Shah et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

Add to Collection

Article Oncology

1274PA prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients

D P Hurkmans et al.

ANNALS OF ONCOLOGY (2019)

Add to Collection

Letter Oncology

Recurrence of Immune-Mediated Colitis Upon Immune Checkpoint Inhibitor Resumption: Does Time Matter?

Julie Delyon et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Article Oncology

Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors

Emma C. de Moel et al.

CANCER IMMUNOLOGY RESEARCH (2019)

Add to Collection

Article Medicine, General & Internal

Variation in the Assessment of Immune-Related Adverse Event Occurrence, Grade, and Timing in Patients Receiving Immune Checkpoint Inhibitors

David Hsiehchen et al.

JAMA NETWORK OPEN (2019)

Add to Collection

Article Medicine, General & Internal

Acute cerebellar ataxia due to Epstein-Barr virus under administration of an immune checkpoint inhibitor

Hirotaka Saikawa et al.

BMJ CASE REPORTS (2019)

Add to Collection

Review Medicine, General & Internal

Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease A Systematic Review

Noha Abdel-Wahab et al.

ANNALS OF INTERNAL MEDICINE (2018)

Add to Collection

Article Oncology

High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma

Alexander T. Faje et al.

CANCER (2018)

Add to Collection

Article Oncology

Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study

Scott Gettinger et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection

Article Medicine, General & Internal

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

Alexander M. M. Eggermont et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Review Rheumatology

Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen

Laura C. Cappelli et al.

SEMINARS IN ARTHRITIS AND RHEUMATISM (2018)

Add to Collection

Article Oncology

Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC

Fernando C. Santini et al.

CANCER IMMUNOLOGY RESEARCH (2018)

Add to Collection

Article Respiratory System

Nivolumab induced vitiligo-like lesions in a patient with metastatic squamous cell carcinoma of the lung

Kazumi Nishino et al.

JOURNAL OF THORACIC DISEASE (2018)

Add to Collection

Article Oncology

Trial Reporting in Immuno-Oncology (TRIO): an American society of clinical oncology-society for immunotherapy of cancer statement

Apostolia M. Tsimberidou et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)

Add to Collection

Article Oncology

Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma

M. H. Pollack et al.

ANNALS OF ONCOLOGY (2018)

Add to Collection

Article Dermatology

Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies are clinically and biologically distinct from vitiligo

Maiana Larsabal et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)

Add to Collection

Article Oncology

Smoldering myocarditis following immune checkpoint blockade

Timothy G. Norwood et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)

Add to Collection

Meeting Abstract Oncology

FDA analysis of patients with baseline autoimmune diseases treated with PD-1/PD-L1 immunotherapy agents.

Chana Weinstock et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

Add to Collection

Article Pathology

Hypophysitis Secondary to Cytotoxic T-Lymphocyte-Associated Protein 4 Blockade Insights into Pathogenesis from an Autopsy Series

Patrizio Caturegli et al.

AMERICAN JOURNAL OF PATHOLOGY (2016)

Add to Collection

Review Multidisciplinary Sciences

Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports

Noha Abdel-Wahab et al.

PLOS ONE (2016)

Add to Collection

Review Rheumatology

Immune checkpoint receptors in regulating immune reactivity in rheumatic disease

Sabrina Ceeraz et al.

ARTHRITIS RESEARCH & THERAPY (2014)

Add to Collection

Article Immunology

Diversity of Antigen-Specific Responses Induced In Vivo with CTLA-4 Blockade in Prostate Cancer Patients

Serena S. Kwek et al.

JOURNAL OF IMMUNOLOGY (2012)

Add to Collection

Review Rheumatology

Effect of biotherapies on fatigue in rheumatoid arthritis: a systematic review of the literature and meta-analysis

Karine Chauffier et al.

RHEUMATOLOGY (2012)

Add to Collection

Review Immunology

The PD-1 pathway in tolerance and autoimmunity

Loise M. Francisco et al.

IMMUNOLOGICAL REVIEWS (2010)

Add to Collection

Article Oncology

Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

Julie R. Brahmer et al.

JOURNAL OF CLINICAL ONCOLOGY (2010)

Add to Collection

Review Immunology

Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways

Brian T. Fife et al.

IMMUNOLOGICAL REVIEWS (2008)

Add to Collection

Article Rheumatology

Fatigue in rheumatoid arthritis reflects pain, not disease activity

L. C. Pollard et al.

RHEUMATOLOGY (2006)

Add to Collection

Review Pharmacology & Pharmacy

Elimination mechanisms of therapeutic monoclonal antibodies

MA Tabrizi et al.

DRUG DISCOVERY TODAY (2006)

Add to Collection

Article Immunology

PD-L1 is expressed by human renal tubular epithelial cells and suppresses T cell cytokine synthesis

HL Ding et al.

CLINICAL IMMUNOLOGY (2005)

Add to Collection

© Peeref 2019-2024. All rights reserved.